Step 1 topics → Renal → Calcium and Phosphate Handling (PTH / Vitamin D)

Calcium and Phosphate Handling (PTH / Vitamin D)

USMLE Step 1 trap: Confuses PTH's phosphaturic effect in the PCT with calcium-retaining effect in the DCT. PTH inhibits phosphate reabsorption in the PCT (by downregulating NaPi cotransporters), causing phosphaturia, while simultaneously increasing Ca2+ reabsorption in the DCT.

Calcium and phosphate handling is one of the most interconnected hormone stories in renal physiology, and USMLE Step 1 exploits that complexity hard. PTH, vitamin D (calcitriol), and FGF23 each act at multiple sites — bone, kidney, gut — and their interactions create a web of feedback loops that the exam tests from every direction. The core concept is this: PTH raises serum calcium while dumping phosphate in the urine; calcitriol raises both calcium and phosphate via the gut; FGF23 counters phosphate retention by suppressing both renal phosphate reabsorption and calcitriol synthesis. When you understand those three sentences cold, most questions become manageable.

The exam tests this topic through mechanism recall (what does PTH do in the DCT vs. PCT?), clinical application (why is calcitriol low in CKD?), and passage-based reasoning where lab values — PTH, phosphate, calcitriol, alkaline phosphatase — are given and you have to identify the hormonal disturbance or predict downstream effects. A vignette might describe a CKD patient with hyperphosphatemia and ask why their PTH is elevated — that question chains FGF23 → suppressed calcitriol → low serum Ca2+ → secondary hyperparathyroidism in one step.

What makes this tricky is that PTH has opposite effects on calcium and phosphate in the kidney — it retains calcium (DCT) while wasting phosphate (PCT) — and students routinely conflate these. Similarly, calcitriol's primary calcium-raising mechanism is intestinal absorption, not bone resorption, but the bone effect gets all the conceptual attention. FGF23 is the newest player and the most commonly inverted: it suppresses calcitriol synthesis, which is the opposite of what most students intuitively expect a 'compensatory' hormone to do.

From real student decks
89%have cards covering this topic
70%have mature cards
1median lapses in 14 days

Common misconceptions

Common mistake
Wrong: PTH increases phosphate reabsorption in the PCT alongside calcium.
Right: PTH inhibits phosphate reabsorption in the PCT (by downregulating NaPi cotransporters), causing phosphaturia, while simultaneously increasing Ca2+ reabsorption in the DCT.
PTH's renal effects are site-specific and do opposite things to calcium vs. phosphate. In the PCT, PTH downregulates NaPi cotransporters, which blocks phosphate reabsorption and causes phosphaturia — this is intentional, because phosphate would otherwise complex with calcium and lower free Ca2+. In the DCT, PTH upregulates TRPV5 channels and calbindin-D28k to retain calcium. These are separate transporters, separate nephron segments, separate directions. Remembering 'PTH saves calcium, wastes phosphate' prevents the conflation.
Common mistake
Wrong: Calcitriol raises serum calcium primarily by mobilizing bone calcium.
Right: Calcitriol's primary action is increasing intestinal absorption of both calcium and phosphate by upregulating calbindin and apical Ca2+ channels in enterocytes.
Calcitriol raises serum calcium primarily by inducing calbindin synthesis in intestinal enterocytes, which increases transcellular absorption of both calcium and phosphate from the gut lumen. Bone resorption is a real calcitriol effect, but it's secondary and requires PTH co-stimulation to be clinically significant. The exam distinction matters because in vitamin D deficiency, the gut absorption failure is what drives hypocalcemia — and why replacement calcitriol fixes it — not a bone resorption defect.
Common mistake
Wrong: FGF23 rises in CKD to compensate for low calcitriol by stimulating vitamin D activation.
Right: FGF23 rises in CKD due to phosphate retention and actually suppresses renal 1α-hydroxylase, worsening calcitriol deficiency and contributing to secondary hyperparathyroidism.
FGF23 is released by osteocytes when serum phosphate rises, and its job is to lower phosphate — it does this by suppressing NaPi cotransporters in the PCT and, importantly, by suppressing 1α-hydroxylase to reduce calcitriol production. Less calcitriol means less gut calcium absorption, lower serum Ca2+, and therefore more PTH (secondary hyperparathyroidism). In CKD, FGF23 rises dramatically as phosphate accumulates, paradoxically worsening calcitriol deficiency rather than correcting it. Think of FGF23 as anti-phosphate and anti-vitamin D — not a compensatory activator of calcitriol.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. PTH's mechanism at four distinct sites: it stimulates osteoclastic bone resorption (raises Ca2+ and PO4), increases Ca2+ reabsorption in the DCT, inhibits phosphate reabsorption in the PCT (causing phosphaturia), and activates 1α-hydroxylase in the kidney to produce calcitriol.
  2. Calcitriol's primary mechanism for raising serum calcium is upregulating intestinal calcium and phosphate absorption via calbindin and apical Ca2+ channels in enterocytes — not primarily through bone resorption — and its feedback relationship with PTH (calcitriol suppresses PTH secretion).
  3. FGF23's origin (osteocytes/osteoblasts), its phosphaturic effect (inhibits NaPi cotransporters in PCT, mirroring PTH), and critically its suppression of renal 1α-hydroxylase — making it a driver of calcitriol deficiency and secondary hyperparathyroidism in CKD.

Can you avoid these mistakes?

A 45-year-old woman with primary hyperparathyroidism has labs showing serum Ca2+ 11.4 mg/dL, serum phosphate 2.1 mg/dL, and urine phosphate markedly elevated. Serum calcitriol is also elevated. Trace the mechanism of each of these four findings back to excess PTH activity — identifying which nephron segment mediates each effect.
Why does vitamin D deficiency cause hypocalcemia even if PTH is elevated and bone resorption is ongoing? What does this tell you about calcitriol's most important site of action?
A patient with stage 4 CKD has high serum phosphate, low calcitriol, and elevated PTH. Explain the hormonal sequence — starting from phosphate retention — that produces this combination of findings. What role does FGF23 play?
A patient with stage 4 CKD has been told his FGF23 is markedly elevated. His nephrologist explains that despite high FGF23, his calcitriol is actually low — not high — and this is worsening his secondary hyperparathyroidism. Explain why FGF23 produces this seemingly paradoxical result, and contrast its downstream effect on calcitriol with what PTH does at the same enzyme.

Related topics

Proximal Tubule Transport Distal Convoluted Tubule Transport Renal Hormones (EPO, Calcitriol, Renin) Kidney Development (Pro-/Meso-/Metanephros) Congenital Renal Anomalies Nephron Structure and Segments

See how your Anki deck covers this topic.

Upload your deck for a free audit →